Ctrip Continues Growing Though Its Bottom Line Remained Dampened Due To Investments
Ctrip released its Q2 2016 results on August 31st. On the domestic front, Ctrip continues making profit through its high end hotel rooms while it uses the funds to subsidize the rates for the low and medium budget hotels. Ctrip’s stake at Qunar is helping the company in providing an entire gamut of hotel rooms along with consolidating the Chinese OTA market. Currently, the company might be looking for opportunities to expand globally, especially to geographies such as the U.S. For Q2 2016, Ctrip’s net loss amounted to $78 million as compared to a net income of $23 million in Q2 2015. Ctrip’s investments into its acquired entities was one of the reasons for the bottomline erosion. Ctrip’s focus currently is on the Chinese outbound travelers and it aims to expand the international products and services to target more travelers.
Have more questions about Ctrip? See the links below.
- What Is Ctrip’s Revenue And EBITDA Breakdown?
- How Has Ctrip’s Revenue And EBITDA Composition Changed Over 2012-2016E?
- Ctrip Q4 2015 Pre-Earnings Report
- What Drove Ctrip’s Revenue Growth And Led To Its EBITDA Decline Over The Last Five Years?
- Ctrip: Year 2015 In Review
- Ctrip Q1 2016 Earnings Preview
- Where Can Ctrip’s Growth Come From In The Next 5 Years?
- Which Two Segments Are The Biggest Contributors To Ctrip’s Growth?
- How Fast Is Ctrip’s Hotel Revenue Growing?
- How Can Ctrip’s Expansion In Geographies Like The U.S. Impact Its Share Price?
- How Did The Brexit Decision Impact Ctrip So Far?
- Ctrip Q2 2016 Earnings Preview
Notes:
See More at Trefis | View Interactive Institutional Research (Powered by Trefis)
- Dropping 8% Year To Date, Will McDonald’s Stock Recover Post Q1 Results?
- Down 6% YTD, Will Restaurant Brands Stock Gain Following Q1 Results?
- IQOS Helps Philip Morris Navigate Well In Q1
- Down 45% Year To Date, What’s Happening With Sirius Stock?
- Meta Platforms Stock Dropped 10.6% In A Day, What’s Next?
- What Factors Will Drive Pfizer’s Q1 Performance?